Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Gains from Investment Securities (2016 - 2025)

Tg Therapeutics (TGTX) has 9 years of Gains from Investment Securities data on record, last reported at $845000.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 1026.67% year-over-year to $845000.0; the TTM value through Dec 2025 reached $2.3 million, up 3026.67%, while the annual FY2025 figure was $7.9 million, 10405.33% up from the prior year.
  • Gains from Investment Securities reached $845000.0 in Q4 2025 per TGTX's latest filing, down from $4.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.7 million in Q3 2023 and bottomed at $75000.0 in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $1.6 million, with a median of $504500.0 recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: crashed 76.06% in 2021, then soared 1026.67% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $474000.0 in 2021, then grew by 7.59% to $510000.0 in 2022, then plummeted by 62.25% to $192500.0 in 2023, then crashed by 61.04% to $75000.0 in 2024, then skyrocketed by 1026.67% to $845000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $845000.0 in Q4 2025, $4.4 million in Q2 2025, and $4.5 million in Q1 2025.